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Background: Gaucher disease (GD) is a rare recessively inherited disorder caused by deficiency of a lysosomal
enzyme, glucocerebrosidase. Accumulation of glucosylceramide or glucosylsphingosine in macrophages leads to
increased production of ferritin and chitotriosidase and to decreases in hemoglobin concentration and platelet
count, which are used as blood biomarkers. GD is treated by enzyme replacement therapy (ERT) or, sometimes by
substrate reduction therapy. However, no physiological model for analysis of biomarkers change during ERT has
been proposed. We aimed to develop a pathophysiological model to analyze biomarker’s response to ERT and
several covariates impact.
Methods: Changes in blood ferritin, chitotriosidase, hemoglobin and platelets were analyzed in French GD Registry
patients receiving imiglucerase/alglucerase as ERT. We used simplified exponential pathophysiological model, with
initial concentration, biomarkers amplitude of variation and rate constant of normalization during ERT. Changes
in four biomarkers were analyzed separately and then all four together from initiation to discontinuation of ERT,
or until the end of follow-up. Several covariates were tested, including age at ERT initiation, splenectomy, sex,
genotype (N370S/N370S), and ERT dose.
Results: An exponential model gave a good data fit. The four biomarkers analysis showed that the rate of
nomalization was the same for all biomarkers, with a half-life of 0.5 years. Predicted values of biomarkers at ERT’s
steady state were 40% and 10% of initial concentrations, for ferritin and chitotriosidase, respectively, and 120% and
200% for hemoglobin and platelets, respectively. We found that 3 covariates had an effect on initial concentration
or on amplitude of variation in ferritin, hemoglobin and platelets: women and patients under 15 years of age had
lower ferritin and hemoglobin concentrations, and patients under 15 years of age had higher platelet count.
Splenectomized patients had higher ferritin concentrations and platelet count and lower amplitude of variation
of hemoglobin.
Conclusion: We report the first dynamic model of biomarker changes in GD. It enabled us to estimate that 95%
of biomarker response to ERT was achieved in 2 years, but with high inter-patient variability. We also found that
with the current treatment, normalization of chitotriosidase and ferritin will occur in about 65% of patients.
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Gaucher disease (GD) [1] is a recessively inherited lyso-
somal storage disorder caused by deficiency of a lyso-
somal enzyme, glucocerebrosidase (EC 3.2.1.45), which
leads to insufficient clearance of the enzyme’s substrate,
cellular glucosylceramide. Pathologic accumulations of
glucosylceramide (or other substrates, such as glucosyl-
sphingosine) in the lysosomes of tissue macrophages
(Gaucher cells) results in splenomegaly, hepatomegaly
and multiple forms of skeletal disease [2]. Three clinical
phenotypes have been described: type 1, the prevalent
form usually defined by the absence of central nervous
system impairment; and types 2 and 3, both rare and
severe, have central neurological involvement [3]. GD
diagnosis is confirmed by the detection of low gluco-
cerebrosidase activity, usually less than 30% of the normal
value in peripheral leukocytes. Genotyping can sometimes
provide prognostic information [4]. More than 250 muta-
tions of the GBA1 gene encoding lysosomal glucocerebro-
sidase have been reported as being associated with GD,
but the predominant mutation in type 1 GD is called
N370S (or c.1226A >G) [5]. The N370S mutation is
usually protective against neuronopathic disease. GD can
be treated by enzyme replacement therapy (ERT). The first
enzyme preparation used to treat GD consisted of
placenta-derived glucocerebrosidase (alglucerase available
in 1991, Genzyme Corporation) with modified mannose-
terminated glycans, allowing more selective uptake by
tissue macrophages, the prominent storage cells in GD
[6-8]. This preparation was replaced in 1996 by recombi-
nant enzyme (imiglucerase), which was therapeutically
equivalent in terms both of safety and efficacy [9]. Two new
biosimilar agents are now available: velaglucerase-alfa
(Shire) [10] and taliglucerase-alfa (Pfizer) [11]. ERT reduces
macrophagic substrate accumulation, but no routine
substrate assay is currently available. A substrate reduction
therapy (miglustat, Actelion) that can be prescribed in a
few indications has been available since 2002.
The levels of several biomarkers (e.g., in our article,
ferritin and chitotriosidase, but also tartrate-resistant
acid phosphatase or angiotensin-converting enzyme, not
analyzed in this study) change during the clinical course
of GD [12-14] due to macrophagic activation: their con-
centrations rise with disease progression and generally de-
crease during ERT [12,15,16]. These variations can predict
bone complications [17]. High blood ferritin during the
course of type 1 GD may reflect macrophage activation trig-
gered by substrate accumulation, demonstrated by increases
in CCL18 and macrophage inflammatory protein-1α or 1β
[18,19]. ERT is associated with a dramatic decrease of blood
ferritin [16,17], which is more pronounced in patients with
an intact spleen [20]. Chitotriosidase is massively produced
by storage cells and there is a linear relationship be-
tween chitotriosidase and glucosylceramide levels, asshown in spleen sections from patients with GD [21].
Chitotriosidase values drop sharply during ERT, when
substrate accumulation decreases, coinciding with
clinical improvements [12].
Hematological abnormalities (anemia and thrombo-
cytopenia) are common in GD, because Gaucher cell in-
filtration leads to hypersplenism (increased destruction
or sequestration of red blood cells or platelets) and bone-
marrow insufficiency (decreased production) [22]. Splenec-
tomy, performed essentially before 1991, increases baseline
platelet count and decreases the slope of platelet clearance
during ERT [17]. Anemia and thrombocytopenia can be
used as biomarkers to manage GD patients.
Grabowski et al. [23] developed an Emax model to de-
scribe changes in hemoglobin and platelets and in splenic
and hepatic volume during ERT of patients in the Inter-
national Collaborative Gaucher Group Registry. Biomarkers
of French GD patients from a single center was modeled
before and during ERT by Stirnemann et al. [17], but no
physiological model was proposed to analyze changes in
biomarkers levels during ERT. Nonlinear mixed effects
models [24] are widely used to analyze biological processes
described by repeated longitudinal data. They allow estima-
tion of the mean value of the parameters and their inter-
individual variability. These models allow a sparse sampling
design with few data points per individual in a large set of
individuals.
The aim of this study was to develop a pathophysiological
model explaining the response of biomarkers (ferritin,
chitotriosidase, hemoglobin, platelets) to ERT and to
analyze the influence of several covariates.
Patients and methods
Patients and data
We analyzed changes in four biomarkers, ferritin, chitotrio-
sidase, hemoglobin and platelets, in patients receiving ERT
with alglucerase from 1991 to 1996 and thereafter imigluce-
rase, from the French GD Registry (FGDR) [25]. The
French Data Protection Commission (CNIL) approval of
the FGDR required oral or written informed consent from
patients or their parents. The local Institutional Review
Board of Northern Paris Hospitals, Paris–Diderot University,
AP–HP (Ethics Committee) reviewed and approved the
initial research project (220–08). These patients were in-
cluded in the study if the last follow-up visit was between
2009 and 2010. This investigation was undertaken to de-
scribe changes in biomarkers from initiation of ERT until
31 December 2010 corresponding to the limit of collected
retrospective data in the FGDR. These data correspond
also to those used in the first description of patients of the
FGDR [25]. All measurements of biomarkers from 2 years
before the initiation of ERT to discontinuation of ERT
(interruption of more than 6 months) or the end of follow-
up (December 2010) were used. When the chitotriosidase
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gous chitotriosidase-gene deficiency), this biomarker was
not retested [26] and the data were not included in the
analysis. When ERT was interrupted for less than 6 months,
patients were considered to be still under treatment.
Several covariates were tested including age at initiation of
ERT, splenectomy, genotype (N370S/N370S or others), sex,
dose at initiation of treatment (divided into 3 classes: lower
than 90 IU/kg/month, between 90 and 120 IU/kg/month
or higher than 120 IU/kg/month) and average dose in the
third year of treatment (divided into the same 3 classes) for
patients followed up for at least 3 years.
Model for biomarker changes during ERT
We defined a pathophysiological model [27] of GD and
treatment by ERT (Figure 1). GD is caused by a gluco-
cerebrosidase deficiency that leads to an accumulation
of glucosylceramide, which is no longer degraded. As a
consequence, there is an increase in ferritin and chito-
triosidase production. With ERT, patients are supplied
with glucocerebrosidase which leads to the degradation
of the glucosylceramide and then improvements of bio-
markers levels. The differential equation of this model
for chitotriosidase is presented in Supplementary mater-
ial (Additional file 1). As only biomarker measurements
were available, we made a further simplification. Since
the rate constant of biomarker elimination is very rapidFigure 1 Scheme of the effect of Gaucher disease on biomarkers an
Plus sign (+) indicates stimulation and minus sign (−) indicates inhibitio
rate of λ B: Simplified model of changes in biomarkers during ERT. Left:
biomarkers that increase during ERT (hemoglobin, platelets). C0 is initial
corrected value at steady state of ERT.compared with the rate constant of normalization of
glucosylceramide under treatment (k), it was neglected
so that we have an exponential increase for chitotriosi-
dase. For chitotriosidase activity, the model is:
C tð Þ ¼ C0 r þ 1−rð Þ exp −ktð ÞÞ½ 
where C0 is the initial concentration, r is the amplitude of
variation and k is the rate constant of normalization during
ERT. For serum ferritin, a similar reasoning leads to the
same equation. From the model, we can derive the
corrected values of biomarkers at steady state of ERT as
C0r (Figure 1) and the normalization half-life as
log 2ð Þ
k .
Even though two different mechanisms explain hema-
tological abnormalities (destruction by hypersplenism
and decrease hematopoiesis), we proposed to simplify
the model with only one predominant mechanism
(destruction). By similar reasoning, for hemoglobin
and platelets, the model is:
C tð Þ ¼ C0 1þ r−1ð Þ 1− exp −ktð Þð Þ½ 
which increases from C0 to C0r (Figure 1).
Statistical analyses
We used a nonlinear mixed effects model to analyze
measurements of the four biomarkers. First, we performed
a separate analysis of each biomarker. We assumed and the effect of ERT. A: Mechanistic pathophysiological model.
n. C is chitotriosidase produced at a rate of R and removed at a
biomarkers that decrease during ERT (ferritin, chitotriosidase); right:
concentration, k rate of decrease (or increase) and C0r estimated
Table 1 Patient characteristics
No.* Value
Sex, n (%) 233
Female 118 (50.6)
Male 115 (49.4)
Age, years, median (range) [IQR]
Diagnosis 233 14.5 (0.5-67.5)
[8.4;34.0]
Initiation of ERT 233 34.3 (1.0-76.0)
[20.6;48.0]
Patients <15 at diagnosis, n (%) 233 87 (62.7)
Patients <15 at initiation of ERT, n (%) 233 41 (17.6)












Initial test leading to GD diagnosis†,
n (%)**
153
Enzyme assay 34 (22.2)




Bone-marrow biopsy 13 (8.5)
Bone biopsy 5 (3.3)
Liver biopsy 3 (1.9)
Spleen histology 17 (11.1)
Other 1 (0.7)
Splenectomy at initiation of ERT, n (%) 233 61 (26.2)
Patients with bone events, n (%)
At initiation of ERT 233 65 (27.9)




< 90 IU/kg/month 28 (13.1)
90- 120 IU/kg/month 174 (81.7)
> 120 IU/kg/month 11 (5.2)
GBA= glucosidase-β acid. *No. represents the number of patients with available
information.
† Several symptoms for each patient. **All patients had diagnosis confirmed
by enzymatic assay.
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random effects have a normal distribution with a mean of 0
and a standard deviation of ω. The residual error model
was supposed to be proportional with a standard deviation,
σ. We also tested the correlation between random effects.
Model selection was performed using the Bayesian infor-
mation criterion (BIC) which adds to the log-likelihood
penalty increases with the number of model parameters
and the sample size used (BIC = −2 × logL + k log (N)),
where L is the maximum likelihood, k is the number of
model parameters and N is the number of patients. BIC is a
parsimonious criterion where the lowest value corresponds
to the best model. We compared our exponential model
with the Emax model of Grabowski et al. [23] using
the BIC.
We tested the impact of the covariates mentioned
above to explain part of the variability [28]. As only
discrete covariates were considered, the effect of the
covariate is to change the parameter by exp(β) where β
is the estimated regression coefficient. The final model
was built using a two-step approach. In the first step,
individual empirical Bayesian estimates of parameters
were generated from the basic model without covari-
ates. We searched for univariate associations with
covariates using Wilcoxon or Spearman tests. In the
second step, all covariates with a p-value of < 0.2 were
entered into a multivariate model. We then performed
a multivariate analysis using a forward selection. P-
values of the Wald test were assessed at the 0.05 level.
Splenectomy has an impact on changes in platelet
count [17]. So we considered (and tested) that splenec-
tomy has an impact on the initial platelet count and on
its amplitude of variation.
We then analyzed the 4 biomarkers jointly and evaluated
whether one or more parameters were correlated or if sev-
eral parameters had similar values, to simplify the model.
We evaluated the final model with various goodness-of-fit
plots [29]: individual fits, graphs of individual weighted
residuals versus time and visual predictive check. The sig-
nificant covariates obtained previously in models of each
biomarker were added. Then, we performed a backward
selection and computed the P-values of the Wald test. Fol-
lowing estimation of population parameters, we could esti-
mate individual parameters. Individual empirical Bayesian
estimates were obtained as maximum a posteriori. From
the individual parameters, we estimated individual half-life,
time to 95% of response (as 4.3 half-lives), values of bio-
markers at steady state of treatment and whether this value
is normal or not.
Estimations were performed using the Stochastic Ap-
proximation Expectation Maximization (SAEM) algorithm
in MONOLIX 4.2.0 (Lixoft, Orsay, France, available at
http://www.lixoft.com) [30]. BIC and log-likelihood were
estimated by importance sampling.
Figure 2 Spaghetti plot of biomarker concentration versus time during ERT for A) ferritin, B) chitotriosidase, C) hemoglobin and D)
platelets. Time 0 corresponds to initiation of ERT, vertical gray line. Green lines correspond to non-splenectomized patients and red lines to
splenectomized patients. Gray horizontal lines correspond to the limit of usual values: ferritin <250 μg/L, chitotriosidase <100 nmol/mL/h,
hemoglobin >12 g/dL, platelet count >150 000/mm3.
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Patient characteristics
In the FGDR, 233 patients receiving imiglucerase had a
medical visit in 2009 or 2010. The diagnosis of GD was
confirmed biochemically in all patients, demonstrating a
deficiency of glucocerebrosidase activity either in leukocytes
or in a fibroblast cell line. Their median (range) follow-up
with ERT was 9 (0–19) years. Median age at the initiation
of ERT was 34.3 (1.0-76.0) years, with 18% < 15 years of
age, 115 (49.4%) were male, and 61 (26.2%) had a splenec-
tomy before the initiation of the ERT. Twenty-six (11.1%)
were N370S/N370S homozygotes. Other characteristics ofthe patients are presented in Table 1. The median (range)
dose at initiation of ERT was 120 IU/kg/month (28 IU/kg/
month - 240 IU/kg/month) with 169 (79.0%) patients with
120 IU/kg/month. The average dose during the third year
was lower than 90 IU/kg/month for 40 (17.4%) patients,
higher than 120 IU/kg/month for 13 (5.7%) and between 90
and 120 IU/kg/month for 176 (76.9%). In some patients
there was no monitoring of biochemical parameters during
follow-up, or monitoring of only one of the four
biomarkers. Therefore, data were available for 129, 142, 191
and 191 patients with a total number of observations of
586, 596, 1287, and 1336 for ferritin, chitotriosidase,
Table 2 Values of fixed effects and variabilities for the
final model of 4 biomarkers without covariates
Fixed effects Estimates RSE (%) P-value
C0F ( μg/L) 598 8
C0C (nmol/h.mL) 7920 11
C0H (g/dL) 11.6 1
C0P (/mm
3) 74300 4





exp(β_ splen) 0.5 19 10−7
k (years−1) 1.4 10
Variabilities
ω_ C0F 83 8
ω_C0C 120 7











C0 is initial concentration, r amplitude of variation and k the rate of normalization
during ERT. F corresponds to ferritin, C to chitotriosidase, H to hemoglobin and
P to platelets. The P-value is for the Wald test. Exp β represents the effect of the
covariates. Splen corresponds to the covariate splenectomy. ω: standard deviation
of inter-individual variability, σ: standard deviation of proportional residual error.
RSE: relative standard error. For example, baseline ferritin concentration is
C0F =598 μg/L, and the estimated corrected value at steady state of ERT
is C0F × rF = 179.4 μg/L. Baseline platelet count in non-splenectomized
patients is C0P = 74,300/mm
3 and C0P exp(β _ splen) = 185,750 /mm
3 in
splenectomized patients. The estimated corrected platelet count at steady
state of ERT in splenectomized patients is (C0P × exp(β _ splen)) × (r0 × exp(β
_ splen)) = 195,037 /mm3.
Table 3 Estimated individual characteristics of biomarker





Half-life of response (years) 0.5 (0.01-3.1)
Time to 95% of response
(years)
2.1 (0.4-13.4)
Ratio (level at steady state/level
at ERT initiation)
Ferritin (%) 38.1 (2.1-101.5)
Chitotriosidase (%) 10.1 (0.8-116.7)
Hemoglobin (%) 117.3 (88.6-173.1)
Platelets (%) 200.4 (83.5-437.8)
Predicted value at steady state
Ferritin (μg/L) 202.0 (16.5-1280.1) 115 (58.4)
Chitotriosidase (nmol/h.mL) 820 (8–18183) 131 (66.5)
Hemoglobin (g/dL) 13.5 (8.1-17.2) 174 (88.3)
Platelets (/mm3) 172 000 (48 000–526
000)
126 (64.0)
Normalization was defined by: ferritin <250 μg/L, chitotriosidase <100 nmol/
mL/h, hemoglobin >12 g/dL, platelet count >150 000/mm3.
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follow-up during ERT was 5 years for ferritin and 6 years
for the other biomarkers. Over 65% of the patients were
followed up for more than 3 years.Changes in biomarkers
Figure 2 shows the individual changes in each biomarker
during ERT in a spaghetti plot. The exponential model
fitted the data. Comparison of our exponential model with
the Emax model gave a gain BIC of 3 for ferritin, 12 forchitotriosidase, and 22 for platelets for our model and a loss
of 7 for hemoglobin. We tested the impact of covariates in
the model of separate biomarkers and found that 3 covari-
ates (initiation of ERT < 15 years of age, splenectomy and
sex) had an effect on the initial concentration and/or on
the amplitude of variation in ferritin, hemoglobin and plate-
lets. Genotype and dose had no significant impact on the
parameters and none of the covariates had a significant
impact on chitotriosidase.
The best model of analysis of the four biomarkers
together was the one with the same parameter k for
all biomarkers, so we considered a rate constant of
normalization during ERT common to the four bio-
markers. The model with the same parameter k had a
smaller BIC of 22 than the model with 4 different
values for parameters k. Values of parameters without
covariates (only splenectomy for platelets) are given in
Table 2 and Table 3: Predicted values of biomarkers at
steady state of ERT were 38% and 10% of initial concentra-
tions, for ferritin and chitotriosidase, respectively, and 117%
and 200% for hemoglobin and platelets, respectively.
Estimated corrected values at steady state of ERT were
179.4 ng/L, 792 nmol/h.mL and 13.9 g/dL for ferritin,
chitotriosidase and hemoglobin, respectively. The
estimated corrected platelet counts at steady state of
ERT were 156,030/mm3 and 195,037/mm3 for non-
splenectomized and splenectomized patients, respect-
ively. Individual predicted values show that, under
current ERT, normalization will occur for 58% of the
patients for ferritin, 66% for chitotriosidase, 88% for
hemoglobin and 64% for platelets. Figure 3 shows
Figure 3 Individual fits for two patients of biomarkers versus time during ERT for A) ferritin, B) chitotriosidase, C) hemoglobin and D)
platelets for two patients. Top: splenectomized patient with red dots. Bottom: non-splenectomized patient with green dots. The black line
corresponds to the curve predicted by the model. Time 0 corresponds to initiation of ERT, vertical gray line. Gray horizontal lines correspond
to the limit of usual values: ferritin <250 μg/L, chitotriosidase <100 nmol/mL/h, hemoglobin >12 g/dL, platelet count >150 000/mm3.
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non-splenectomized. Relative standard errors were
lower than 20% for both fixed effects and variabilities.
Diagnostic plots (Additional file 2) show that the
model describes the data adequately.
Values of parameters in the joint model with covariates
are given in Table 4. The covariate effects were the same as
in the models considering the biomarkers separately.
Figure 4 shows the response of the biomarkers to ERT,
according to significant covariates. Non-splenectomized
(p-value = 10−6) and age <15 years (p-value < 10−10) patients
had a lower initial concentration of ferritin. Women
(p-value = 0.002) and non-splenectomized (p-value = 10−4)
patients had a lower amplitude of variation in ferritin.
Women (p-value = 0.01) and age <15 years (p-value = 10−8)
patients had a lower initial concentrations of hemoglobin.
Splenectomized (p-value = 10−5) patients had a lower
amplitude of variation in hemoglobin. Splenectomized
(p-value < 10−10) and age <15 years (p-value = 10−6)
patients had a higher initial platelet count. Splenecto-
mized (p-value = 10−8) patients had a lower amplitude
of variation in platelets.In the final model, we estimated that during ERT the
half-life of normalization was 0.5 years (95% CI = [0.4-
0.6]), with a variability of 97%. Half-life was 0.5 (0.1-3.1)
years and 95% of response was obtained after 2 (0.4-
13.3) years under ERT. Variabilities were reasonable for
ferritin, hemoglobin and platelet count. Greater variabi-
lity was found for chitotriosidase, doubtless because of
variability in measurement error (a sample dilution is
usually needed when values are high).
Discussion
Our pathophysiological model predicts changes in bio-
markers on ERT and estimates the rate constant of
normalization. For the final model, we estimated a
normalization half-life of 0.5 years during ERT for all
four biomarkers. Only 2 studies have modeled the
changes in biomarkers and they used different models:
Emax and linear mixed models. In the study of Grabowski
et al. [23], the ERT dose effect had a significant impact
on biomarkers with a large sample size. Emax is an
empirical model with a hyperbolic function; it is not
the result of a physiological model. These models are
Table 4 Values of fixed effects and variabilities for the
final model with significant covariates
Fixed effects Estimates RSE (%) P-value
C0F ( μg/L) 603 9
exp(β_ splen) 1.9 24 10−6
exp(β_ < 15) 0.3 14 < 10−10
C0C (nmol/h.mL) 8140 12
C0H (g/dL) 11.6 1
exp(β_ man) 1.1 40 0.01
exp(β_ < 15) 0.9 19 10−8
C0P (/mm
3) 68400 4
exp(β_ splen) 2.7 8 < 10−10
exp(β_ < 15) 1.4 24 10−6
rF 0.3 13
exp(β_ splen) 0.5 29 0.0005
exp(β_ man) 1.7 32 0.002
rC 0.1 14
rH 1.2 1
exp(β_ splen) 0.9 25 10−5
rP 2.2 4
exp(β_ splen) 0.7 19 10−8
k (years−1) 1.4 11
Variabilities
ω_ C0F 63 8
ω_C0C 122 7











C0 is initial concentration, r amplitude of variation and k the rate of
normalization during ERT. F corresponds to ferritin, C to chitotriosidase,
H to hemoglobin and P to platelets. The P-value is for the Wald test. exp β
represents the effect of the covariates. Splen corresponds to the covariates
splenectomy, <15 indicates patients under 15 years of age and man indicates
the covariate sex. ω: standard deviation of inter-individual variability,
σ: standard deviation of proportional residual error. RSE: relative standard error.
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dose and concentration. However, the drug often acts on
a biological quantity, modifying its production or elimi-
nation. We modeled this quantity by a model with a pro-
duction rate and a rate constant of elimination. Usingphysiological knowledge, we obtained differential equations
to explain changes in biomarkers over time. For instance,
90% response is obtained after 9 T50 for an Emax model,
whereas it is reached after only 3.3 half-lives (similar
to T50) for an exponential model.
Our results show improvement in all biomarkers
under ERT (decrease in ferritin and chitotriosidase and
increase in hemoglobin and platelets). Stein et al.
[20] also highlighted an increase in ferritin and a
renormalization under ERT. Hollak et al. [31] reported a
decrease of chitotriosidase of 32% in 1 year, and we found
a 95% response in 2 years and a 36% response in 1 year.
De Fost et al. [32] reported that 53% of patients had
anemia at baseline and 58% had thrombocytopenia, with
renormalization under ERT, and showed a similar pattern
of response after 1 year under ERT.
Patients <15 years of age have lower initial concentra-
tions of ferritin and hemoglobin but higher platelet
counts; at initiation of ERT, women have a lower con-
centration of hemoglobin and splenectomized patients
have a higher platelet count and ferritin. For GD chil-
dren from the International Collaborative Gaucher
Group Registry, Kaplan P et al. [33] noted that 50% had
platelet counts less than 120 × 103/mm3 and 40% had
anemia at the time of diagnosis. Hemoglobin and ferritin
tend to be lower in GD women, as for other women, prob-
ably because of menstruation, with no link to GD. In our
model, no covariates had a significant impact on the chito-
triosidase changes. In contrast, Stirnemann et al. [17] found
that splenectomy and GD genotype affected chitotriosidase
activity, but their study was limited by a small number of
samples, and they used a different model.
Our model allows estimation of the rate constant of
biomarker improvement using a pathophysiological
model. Bone events are the most debilitating and dis-
abling complication of GD. With substrate overload,
Gaucher cells activate and induce proinflammatory
cytokine synthesis which can modify the activity of
the osteoblast-osteoclast system and promote lytic
phenomena and intraosseous vascular complications
[34,35]. Further analysis of the interaction between
biomarkers and bone events is needed.
Recently, plasma glucosylsphingosine has been proposed
as a biomarker for GD [36,37] and could be used as a re-
flection of intracellular glucosylceramide. Our model may
also predict changes in intracellular glucosylceramide and/
or glucosylsphingosine.
Our model could be used to study the effect of bio-
marker changes on complications such as the occur-
rence of bone events. Using a few measurements of
biomarkers post-treatment, we can estimate the rate
constant of normalization and individual amplitude of
variation in biomarkers in order to predict further
response to treatment. Our model could help to define
Figure 4 (See legend on next page.)
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Figure 4 Biomarker responses for a median patient for the final model according to significant covariates for ferritin, chitotriosidase,
hemoglobin and platelets. A green line is for non-splenectomized patients and a red line for splenectomized patients. A dotted line is for man
and continuous for woman. For platelets, no distinction between man and woman and change is a continuous line. Initial concentration and
concentrations at steady state of ERT are indicated, in green for non-splenectomized, red for splenectomized patients, and in orange when no
distinction can be made depending on splenectomy. Lines are thin for man and bold for woman. Left: patients <15 years of age. Right:
patients > 15 years of age.
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http://www.ojrd.com/content/9/1/95an individual risk for complications and to refine the
best ERT regimens.
Parameters of this pathological model could be used
to predict value at steady state with the dosages in the
first months of ERT. These predicted values could be
used as an individual objective of treatment to modify
dosage for each patient. Clinical studies are needed to
confirm this hypothesis.
We developed a model which could in the future be
used to manage patients, but further studies are needed
to confirm clinical applications. This model with 2
parameters (in addition to the baseline value) predicts the
level of improvement of biomarkers and the time to 95%
response, using only a few measurements per patient.
Conclusion
This is to our knowledge the first study of changes in
biomarkers in Gaucher disease using a pathophysio-
logical model. With the model we estimate that 95% of
biomarker response to ERT is achieved in 2 years, but
with high inter-patient variability. We also found that
with the current treatment, normalization of chitotriosi-
dase and ferritin will occur in about 65% of patients.
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